340 related articles for article (PubMed ID: 24786783)
1. Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel.
Petri M; Bechtel B; Dennis G; Shah M; McLaughlin T; Kan H; Molta C
Lupus; 2014 Sep; 23(10):1006-13. PubMed ID: 24786783
[TBL] [Abstract][Full Text] [Related]
2. Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus.
Shah M; Chaudhari S; McLaughlin TP; Kan HJ; Bechtel B; Dennis GJ; Molta CT
Clin Ther; 2013 Apr; 35(4):486-97. PubMed ID: 23587268
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus.
Kabadi S; Yeaw J; Bacani AK; Tafesse E; Bos K; Karkare S; DeKoven M; Vina ER
Lupus; 2018 Oct; 27(11):1799-1809. PubMed ID: 30068254
[TBL] [Abstract][Full Text] [Related]
4. Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports.
Bexelius C; Wachtmeister K; Skare P; Jönsson L; Vollenhoven Rv
Lupus; 2013 Jul; 22(8):793-801. PubMed ID: 23761101
[TBL] [Abstract][Full Text] [Related]
5. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
6. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review.
Sarnes E; Crofford L; Watson M; Dennis G; Kan H; Bass D
Clin Ther; 2011 Oct; 33(10):1413-32. PubMed ID: 21999885
[TBL] [Abstract][Full Text] [Related]
7. Costs associated with severe and nonsevere systemic lupus erythematosus in Canada.
Clarke AE; Urowitz MB; Monga N; Hanly JG
Arthritis Care Res (Hoboken); 2015 Mar; 67(3):431-6. PubMed ID: 25185936
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effect of cumulative corticosteroid dose and immunosuppressants on avascular necrosis in patients with systemic lupus erythematosus.
Kwon HH; Bang SY; Won S; Park Y; Yi JH; Joo YB; Lee HS; Bae SC
Lupus; 2018 Sep; 27(10):1644-1651. PubMed ID: 29950160
[TBL] [Abstract][Full Text] [Related]
9. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US.
Slawsky KA; Fernandes AW; Fusfeld L; Manzi S; Goss TF
Arthritis Care Res (Hoboken); 2011 Sep; 63(9):1224-32. PubMed ID: 21584945
[TBL] [Abstract][Full Text] [Related]
10. The impact of flare on disease costs of patients with systemic lupus erythematosus.
Zhu TY; Tam LS; Lee VW; Lee KK; Li EK
Arthritis Rheum; 2009 Sep; 61(9):1159-67. PubMed ID: 19714597
[TBL] [Abstract][Full Text] [Related]
11. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population.
Li T; Carls GS; Panopalis P; Wang S; Gibson TB; Goetzel RZ
Arthritis Rheum; 2009 Jun; 61(6):755-63. PubMed ID: 19479688
[TBL] [Abstract][Full Text] [Related]
12. Development of a Set of Lupus-Specific, Ambulatory Care-Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study.
Feldman CH; Speyer C; Ashby R; L Bermas B; Bhattacharyya S; Chakravarty E; Everett B; Ferucci E; Hersh AO; Marty FM; Merola JF; Ramsey-Goldman R; Rovin BH; Son MB; Tarter L; Waikar S; Yazdany J; Weissman JS; Costenbader KH
Arthritis Care Res (Hoboken); 2021 Jan; 73(1):146-157. PubMed ID: 31628721
[TBL] [Abstract][Full Text] [Related]
13. Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden.
Huang SP; DerSarkissian M; Gu YM; Duh MS; Wang MJ; Benson J; Vu J; Averell C; Bell CF
J Manag Care Spec Pharm; 2023 Apr; 29(4):365-377. PubMed ID: 36989451
[No Abstract] [Full Text] [Related]
14. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.
Garris C; Jhingran P; Bass D; Engel-Nitz NM; Riedel A; Dennis G
J Med Econ; 2013; 16(5):667-77. PubMed ID: 23425294
[TBL] [Abstract][Full Text] [Related]
15. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?
Karp I; Abrahamowicz M; Fortin PR; Pilote L; Neville C; Pineau CA; Esdaile JM
Arthritis Rheum; 2008 Feb; 59(2):169-75. PubMed ID: 18240259
[TBL] [Abstract][Full Text] [Related]
16. The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease.
Khamashta MA; Bruce IN; Gordon C; Isenberg DA; Ateka-Barrutia O; Gayed M; Donatti C; Guillermin AL; Foo J; Perna A
Lupus; 2014 Mar; 23(3):273-83. PubMed ID: 24356612
[TBL] [Abstract][Full Text] [Related]
17. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
Kariburyo F; Xie L; Sah J; Li N; Lofland JH
J Med Econ; 2020 Jan; 23(1):1-9. PubMed ID: 31589081
[No Abstract] [Full Text] [Related]
18. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus.
Compeyrot-Lacassagne S; Tyrrell PN; Atenafu E; Doria AS; Stephens D; Gilday D; Silverman ED
Arthritis Rheum; 2007 Jun; 56(6):1966-73. PubMed ID: 17530722
[TBL] [Abstract][Full Text] [Related]
19. Role of specialty care in the management of patients with systemic lupus erythematosus.
Urowitz MB; Kagal A; Rahman P; Gladman DD
J Rheumatol; 2002 Jun; 29(6):1207-10. PubMed ID: 12064836
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus.
Kan H; Nagar S; Patel J; Wallace DJ; Molta C; Chang DJ
Clin Ther; 2016 Mar; 38(3):610-24. PubMed ID: 26907503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
